Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models

This 2013 study evaluated the effects of oxytocin (OXT) and its analogs on obesity and diabetes. In a randomized pilot clinical trial, obese patients received intranasal OXT for 8 weeks, resulting in significant weight loss and reversal of prediabetic changes. In mouse models, both central and peripheral administration of OXT